Literature DB >> 20807226

Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population.

A H W Bruns1, J J Oosterheert, M C Cucciolillo, R El Moussaoui, R H H Groenwold, J M Prins, A I M Hoepelman.   

Abstract

Insights into long-term mortality, especially into the cause of death after initial recovery from an episode of community-acquired pneumonia (CAP), may help in determining optimal preventive measures in such patients. Prospective observational cohort studies were conducted to compare cause-specific long-term mortality rates for 356 patients who had recovered from CAP with those of the general Dutch population (16.3 million) between 2003 and 2007. The Dutch Municipal Public Records Database and death certificates were used to determine cause-specific mortality rates up to 7 years after discharge. In patients who had recovered from CAP, cumulative 1-year, 5-year and 7-year mortality rates were 17%, 43% and 53%, respectively, as compared with 4%, 19% and 24% for an age-matched and sex-matched population reference cohort. Overall, patients who had recovered from CAP had significantly higher long-term mortality than matched population controls (rate ratio (RR) 3.6; p <0.001). In the years after an episode of CAP, malignancy (27%), chronic obstructive pulmonary disease (COPD) (19%) and cardiovascular disease (16%) were the most frequent causes of death. Only 6% died of pneumonia, as compared with 3.2% in the general population. After initial recovery from an episode of CAP, long-term mortality rates are more than three times as high as in the general population. The causes of long-term mortality were mostly comorbidity-related, and significantly different from those in the general population. After an episode of CAP, optimization of treatment of comorbidities, such as treatment for COPD, might improve long-term survival rates.
© 2010 The Authors. Clinical Microbiology and Infection © 2010 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Year:  2010        PMID: 20807226     DOI: 10.1111/j.1469-0691.2010.03296.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  19 in total

1.  A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia.

Authors:  Marco Falcone; Alessandro Russo; Yuichiro Shindo; Alessio Farcomeni; Filippo Pieralli; Roberto Cangemi; Jinliang Liu; Jingyan Xia; Junya Okumura; Masahiro Sano; Christopher Jones; Vieri Vannucchi; Massimo Mancone; Scott Micek; Feng Xu; Francesco Violi; Marin Kollef
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 2.  Long-term prognosis in community-acquired pneumonia.

Authors:  Marcos I Restrepo; Paola Faverio; Antonio Anzueto
Journal:  Curr Opin Infect Dis       Date:  2013-04       Impact factor: 4.915

Review 3.  The management of community-acquired pneumonia in the elderly.

Authors:  Paola Faverio; Stefano Aliberti; Giuseppe Bellelli; Giulia Suigo; Sara Lonni; Alberto Pesci; Marcos I Restrepo
Journal:  Eur J Intern Med       Date:  2013-12-17       Impact factor: 4.487

4.  Socioeconomic Position and the Incidence, Severity, and Clinical Outcomes of Hospitalized Patients With Community-Acquired Pneumonia.

Authors:  Timothy L Wiemken; Ruth M Carrico; Stephen P Furmanek; Brian E Guinn; William A Mattingly; Paula Peyrani; Julio A Ramirez
Journal:  Public Health Rep       Date:  2020-03-31       Impact factor: 2.792

Review 5.  Cardiotoxicity during invasive pneumococcal disease.

Authors:  Armand O Brown; Elizabeth R C Millett; Jennifer K Quint; Carlos J Orihuela
Journal:  Am J Respir Crit Care Med       Date:  2015-04-01       Impact factor: 21.405

6.  Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; Navneet Singh; Narayan Mishra; G C Khilnani; J K Samaria; S N Gaur; S K Jindal
Journal:  Lung India       Date:  2012-07

7.  Long-term mortality after community-acquired pneumonia--impacts of diabetes and newly discovered hyperglycaemia: a prospective, observational cohort study.

Authors:  Heikki O Koskela; Päivi H Salonen; Jarkko Romppanen; Leo Niskanen
Journal:  BMJ Open       Date:  2014-08-21       Impact factor: 2.692

8.  Pneumonia severity, comorbidity and 1-year mortality in predominantly older adults with community-acquired pneumonia: a cohort study.

Authors:  Thomas Wesemann; Harald Nüllmann; Marc Andre Pflug; Hans Jürgen Heppner; Ludger Pientka; Ulrich Thiem
Journal:  BMC Infect Dis       Date:  2015-01-08       Impact factor: 3.090

9.  Impact of an Educational Program to Reduce Healthcare Resources in Community-Acquired Pneumonia: The EDUCAP Randomized Controlled Trial.

Authors:  Jordi Adamuz; Diego Viasus; Antonella Simonetti; Emilio Jiménez-Martínez; Lorena Molero; Maribel González-Samartino; Elena Castillo; María-Eulalia Juvé-Udina; María-Jesús Alcocer; Carme Hernández; María-Pilar Buera; Asunción Roel; Emilia Abad; Adelaida Zabalegui; Pilar Ricart; Anna Gonzalez; Pilar Isla; Jordi Dorca; Carolina Garcia-Vidal; Jordi Carratalà
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

10.  Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for Community-Aquired Pneumonia.

Authors:  Michael E Egger; John A Myers; Forest W Arnold; Leigh Ann Pass; Julio A Ramirez; Guy N Brock
Journal:  BMC Med Inform Decis Mak       Date:  2016-03-15       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.